Abbott’s Stent Earns CE Mark for Shorter Duration of Dual Anti-Platelet Therapy

Abbott Laboratories’ XIENCE drug-eluting stent has received CE mark certification for delivering a shorter duration of dual anti-platelet therapy in patients with high bleeding risk.

The certification was supported by results from two clinical trials that enrolled more than 3,600 participants and evaluated one-month and three-month treatments followed by aspirin monotherapy, finding that the therapy can be safely discontinued after the shorter treatment.

“Patients who receive the XIENCE stent with shorter dual anti-platelet therapy durations do not have an increase in cardiac events and showed a reduction in severe bleeding, proving short dual anti-platelet therapy strategies with the XIENCE stent are safe in high bleeding-risk patients,” Abbott said.